#targeted therapy

David Reardon, MD, and Patrick Y. Wen, MD, of Dana-Farber Cancer Institute talk targeted therapies and immunotherapy.

Ribociclib now approved for pre- and perimenopausal women with HR-positive, HER2-negative breast cancer.

Twice as many patients were alive 18 months after starting treatment.

Three scientists were recognized for their development of a targeted therapy for treating colon cancer and head and neck cancer.

A new therapy, BLU-667, shows broad antitumor activity against cancers with a variety of RET alterations.

Results strengthen the path forward for targeted cancer therapies.

How researchers are tweaking engineered immune cells’ cancer-targeting receptors—and why it matters.

Using molecular tests to select the most appropriate treatment leads to better outcomes.

The test will look for mutations that are associated with medical conditions ranging from heart disease to cancer.

Four-drug regimen improves response in people being treated for the first time.

Tafinlar and Mekinist approved for a third cancer with specific gene mutation.

Study shows eight-month survival advantage for those not previously treated with chemotherapy.

BLU-667 shrinks thyroid and lung cancers with RET gene alterations.

In three trials larotrectinib shrank tumors in many people whose tumors overexpressed TRK fusion proteins.

Recommendations now include multiple systemic medications in addition to surgery and local therapies.